About Globus Medical, Inc. Class A Common Stock (GMED)
Globus Medical Inc is a medical device company that specializes in the development and commercialization of innovative products for spine surgery. The company focuses on creating solutions that enhance surgical outcomes and improve patient recovery through advanced technologies, including surgical implants, instruments, and robotics. With a robust portfolio, Globus Medical aims to address various spinal conditions and assist healthcare professionals in providing effective treatment options, ultimately striving to elevate the standard of care in spine surgery. Read More
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency.
Globus Medical (NYSE:GMED) is a strong growth stock with solid fundamentals and a potential technical breakout, making it a candidate for investors seeking growth opportunities in the healthcare sector.
Globus Medical (NYSE:GMED) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth in the healthcare sector.
NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Shareholders of Globus Medical would probably like to forget the past six months even happened. The stock dropped 28.9% and now trades at $58.14. This was partly due to its softer quarterly results and might have investors contemplating their next move.
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 billion at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP profit of $0.68 per share was 8.6% below analysts’ consensus estimates.
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Globus Medical (NYSE:GMED) shows strong growth fundamentals and a technical setup suggesting a potential breakout. The stock combines revenue growth, profitability, and a favorable chart pattern.
GLOBUS MEDICAL (NYSE:GMED) is a strong growth stock with reasonable valuation, solid profitability, and a healthy balance sheet, making it an attractive option for investors seeking growth at a fair price.
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
